• Licensing Agreement to Drive Multi-specific Biotherapeutics Development

News & Views

Licensing Agreement to Drive Multi-specific Biotherapeutics Development

Jan 17 2022

Zhejiang Doer Biologics Co, Ltd and Lonza have entered into a research license agreement for Doer Biologics to use Lonza’s XS Technologies® offering for production of its proprietary MultipleBody® and SMART-VHHBody platform technology. Doer Biologics is a clinical-stage biopharmaceutical company focused on the development of multi-domain-based, multi-specific innovative protein drugs in the fields of cancer, endocrinology, metabolic diseases, and ophthalmology. 

The license secures Doer Biologics’ access to Lonza's XS® Pichia Expression System, providing for the development of scalable, robust, and reliable expression processes. This will enable Doer Biologics to develop, express, and manufacture multi-specific VHH based biotherapeutic proteins to address unmet medical needs in the field of immuno-oncology. Doer Biologics noted early success with the Lonza XS® Pichia Expression System in their lab and are pursuing further developments.

Peter Droc, Head of Licensing and Drug Product Services, Lonza, commented: “Next-generation therapies always demand a new take on expression systems. At Lonza, we have continued developing a toolbox of expression systems that help accommodate industry trends, eliminate production bottlenecks, align downstream processing and drive breakthroughs in the clinic. Doer Biologics has innovative R&D pipelines for VHH antibodies and we believe this agreement will further accelerate their candidates from pre-clinical study to commercial manufacturing.”

Dr Yanshan Huang, founder and CEO, Zhejiang Doer Biologics Co Ltd, added: “Multi-specific biologics often show stronger potency, extended half-life, improved therapeutic window, and higher developability compared to single-target antibodies. However, designing and developing new multi-specific antibodies represents a central challenge for the realisation of new immunotherapies. Access to Lonza’s proprietary expression technology will enable us to progress our proprietary MultipleBody® and SMART-VHHBody platform by providing high-yielding processes for our candidates. We believe that we can develop high-quality VHH based multi-specific biotherapeutics in a faster and lower-cost fashion with Lonza’s XS® Pichia Expression System.”

More information online

Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions


Water Expo Nigeria 2024

May 21 2024 Lagos, Nigeria

Discovery Europe 2024

May 22 2024 Basel, Switzerland

NGVS 2024

May 23 2024 Beijing, China


May 28 2024 Tel Aviv, Israel

View all events